This trial is active, not recruiting.

Conditions anal cancer, hiv infections
Treatment gardasil
Sponsor Southern California Institute for Research and Education
Collaborator Merck Sharp & Dohme Corp.
Start date June 2008
End date June 2012
Trial size 150 participants
Trial identifier NCT00666107, #33245


This study will investigate the efficacy and safety of the quadrivalent vaccine (Gardasil) against the human papilloma virus (HPV) in HIV (human immunodeficiency virus) infected males.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose prevention

Primary Outcomes

Determine Geometric Mean Titers of anti-HPV 16 and anti-HPV 18 antibodies
time frame: nine months
Determine percentage of subjects who seroconverted or mounted a significant serologic response to each of the 2 antigens 16 and 18
time frame: 8-9 months
Determine how many patients, if any, develop evidence of anal HPV infection, as measured by development of a positive HPV test.
time frame: 9 months
Determine if vaccinations will activate the subject's immune systems sufficiently that the HIV-1 viral load either increases from the baseline value, or becomes detectable and stays detectable after being undetectable at the baseline visit
time frame: nine months

Eligibility Criteria

Male participants at least 18 years old.

Inclusion Criteria: - Male veterans - Age 18 or older - HIV-positive - Seen regularly in the ID Primary Care Clinic at the VA Long Beach Healthcare System Exclusion Criteria: - None

Additional Information

Official title Pilot Study to Evaluate the Immunogenicity and Safety of the HPV Quadrivalent Vaccine (Gardasil) in HIV-infected Men
Principal investigator Stephen M Berman, M.D., Ph.D.
Description This is a prospective pilot study that will attempt to enroll approximately 150-200 HIV-infected males followed regularly in the ID Primary Care Clinic at the VA Long Beach Healthcare System. All consenting patients will be given the HPV vaccine (Gardasil) in three intramuscular injections. Baseline antibody titers to HPV strains 16 and 18 will be obtained at day 0 and repeat levels will be obtained approximately 8 weeks after the completion of the vaccination series to determine whether patients without antibodies at baseline have now produced antibodies, or to determine the change in antibody levels in those patients who have evidence of antibodies prior to the first injection of the vaccine. Patients will undergo routine anal PAP smear with HPV DNA testing at baseline and another PAP smear/HPV test approximately 8 weeks after completion of the series. Patients will report any side effects of the vaccine to the PI. Patients will have blood work to monitor HIV-1 viral load and CD4 lymphocytes counts at various points during the study.
Trial information was received from ClinicalTrials.gov and was last updated in March 2012.
Information provided to ClinicalTrials.gov by Southern California Institute for Research and Education.